GANX - Company ID 0001819411
The table below shows Gain Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $2.76M | $2.85M | $2.76M | $2.26M | $2.62M | $4.44M |
| SG&A |
Gain Therapeutics, Inc. reported annual revenue of $55.18K for fiscal year 2023. That is down 60.6% from $140.11K in fiscal 2022. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $2.59M |
| $1.94M |
| $2.33M |
| $2.11M |
| $1.84M |
| $3.75M |
| Operating income | -$5.35M | -$4.79M | -$5.09M | -$4.37M | -$4.46M | -$8.18M |
| Income tax | $183.07K | $549.29K | $141.21K | $100.51K | $10.99K | $1.21K |
| Net income | -$5.61M | -$5.28M | -$5.81M | -$4.53M | -$4.49M | -$8.14M |
| EPS (diluted) | -$0.13 | -$0.15 | -$0.19 | -$0.16 | -$0.17 | -$0.42 |